To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Overview

This is a 12-week chronic-dosing study to assess the efficacy and safety of BGF MDI compared to BFF MDI in subjects with moderate to very severe COPD.

Full Title of Study: “A Randomized, Double-Blind, Parallel-Group, 12-Week, Chronic Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: December 7, 2018

Detailed Description

This is a multicenter, randomized, double-blind, parallel-group, 12-week chronic-dosing study to assess the efficacy and safety of BGF MDI compared to BFF MDI in subjects with moderate to very severe COPD. The study has a total of 7 visits over a Screening Period of up to 28 days and a Treatment Period of 12 weeks followed by a telephone follow-up call 14 days after the last dose of study drug.

Interventions

  • Drug: BGF 320/14.4/9.6 µg MDI
    • Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
  • Drug: BFF 320/9.6 µg
    • Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)

Arms, Groups and Cohorts

  • Experimental: BGF 320/14.4/9.6 µg MDI BID
    • Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
  • Experimental: BFF 320/9.6 µg MDI BID
    • Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)

Clinical Trial Outcome Measures

Primary Measures

  • Forced expiratory volume area under the curve from 0 to 4 hours (AUC0-4)
    • Time Frame: Week 12

Secondary Measures

  • Change from baseline in morning pre-dose trough FEV1
    • Time Frame: Week 12
  • Peak change from baseline in inspiratory capacity
    • Time Frame: Week 12
  • Percentage of subjects achieving a minimally clinical important difference (MCID) of 4 units or more in St. George’s Respiratory Questionnaire (SGRQ)
    • Time Frame: Week 12
  • Time to first clinically important deterioration (CID) in COPD
    • Time Frame: 12 weeks
  • Change from baseline in average daily rescue Ventolin HFA use
    • Time Frame: 12 weeks
  • Peak change from baseline in FEV1
    • Time Frame: Week 12
  • Time to onset of action
    • Time Frame: Day 1

Participating in This Clinical Trial

Key Inclusion Criteria:

  • Signed Informed Consent – Subjects with an established clinical history of COPD – Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) ratio must be <0.70 and FEV1 must be <80% predicted normal value – All subjects must have been on 2 or more inhaled maintenance therapies for the management of their COPD for at least 6 weeks prior to Screening – Current or former smokers with a history of at least 10 pack-years of cigarette smoking – Women of Non-childbearing potential – Women of childbearing potential and sexually active agree to prevent pregnancy by using acceptable contraceptive methods consistently Key Exclusion Criteria:

  • Significant diseases or conditions other than COPD, which in the opinion of the Investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study – Women who are pregnant or lactating, or are planning to become pregnant during the course of the study, or women of childbearing potential who are not using an acceptable method of contraception – Current diagnosis of asthma – Uncontrolled sleep apnea – Other Serious Respiratory Disorders – Hospitalized due to poorly controlled COPD within 6 weeks – Poorly Controlled COPD – Immune deficiency and/or severe neurological disorders affecting control of the upper airway – Hypersensitivity to β2-agonists, corticosteroids, or muscarinic anticholinergics

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Pearl Therapeutics, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Colin Reisner, MD, Study Director, Pearl Therapeutics, Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.